Trial Profile
Safety and efficacy of varicella zoster immune globulin (human) VariZIG in patients at-risk of varicella infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Varicella zoster immune globulin (Primary)
- Indications Chickenpox; Herpes zoster
- Focus Expanded access; Therapeutic Use
- 07 Oct 2018 Results (n=505) presented at the IDWeek 2018
- 08 Dec 2008 Planned end date changed from 1 Jul 2007 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 08 Oct 2006 New trial record.